TY - JOUR
T1 - Giant cell tumors of the bone
T2 - Changes in image features after denosumab administration
AU - Oguro, Sota
AU - Okuda, Shigeo
AU - Sugiura, Hiroaki
AU - Matsumoto, Shunsuke
AU - Sasaki, Aya
AU - Susa, Michiro
AU - Morioka, Hideo
AU - Jinzaki, Masahiro
N1 - Publisher Copyright:
© 2018 Japanese Society for Magnetic Resonance in Medicine.
PY - 2018
Y1 - 2018
N2 - Purpose: To assess the clinical importance in the feature change in giant cell tumors of the bone (GCTB) after denosumab treatment, detected by MRI. Methods: In 12 patients, MRI and CT of GCTB obtained before and after the treatment retrospectively compared. The tumor size, the signal intensity (SI) ratio between the solid part of the GCTB and muscle, cystic part size, gadolinium enhancement and apparent diffusion coefficient (ADC) value were measured on MRI. The bone formation in the tumor was observed on CT and X-ray. Results: The mean number of denosumab injections was 19 ± 10. The follow-up period was up to 2 years. One case showed partial remission, while the other 11 cases were stable. A mean SI ratio on T2-weighted image statistically significantly decreased from 3.9 to 1.9 after the treatment. A cystic component in the tumor was observed in five cases before the treatment, and the diameter of the cystic part decreased after the treatment in 80% of cases (4/5). All the tumors showed contrast enhancement on T1-weighted image pre-and post-treatment (11/11). The averaged ADC values were 1.52 × 10−3 mm2/s before and 1.44 × 10−3 mm2/s after the treatment (P = 0.63). Bone formation in the tumor was observed in 58% of cases (7/12). Conclusion: The decrease of SI ratio on T2-weighted image, shrinkage of cystic part and bone formation should be regarded as the effectiveness of denosumab treatment despite of no substantial change in the tumor size.
AB - Purpose: To assess the clinical importance in the feature change in giant cell tumors of the bone (GCTB) after denosumab treatment, detected by MRI. Methods: In 12 patients, MRI and CT of GCTB obtained before and after the treatment retrospectively compared. The tumor size, the signal intensity (SI) ratio between the solid part of the GCTB and muscle, cystic part size, gadolinium enhancement and apparent diffusion coefficient (ADC) value were measured on MRI. The bone formation in the tumor was observed on CT and X-ray. Results: The mean number of denosumab injections was 19 ± 10. The follow-up period was up to 2 years. One case showed partial remission, while the other 11 cases were stable. A mean SI ratio on T2-weighted image statistically significantly decreased from 3.9 to 1.9 after the treatment. A cystic component in the tumor was observed in five cases before the treatment, and the diameter of the cystic part decreased after the treatment in 80% of cases (4/5). All the tumors showed contrast enhancement on T1-weighted image pre-and post-treatment (11/11). The averaged ADC values were 1.52 × 10−3 mm2/s before and 1.44 × 10−3 mm2/s after the treatment (P = 0.63). Bone formation in the tumor was observed in 58% of cases (7/12). Conclusion: The decrease of SI ratio on T2-weighted image, shrinkage of cystic part and bone formation should be regarded as the effectiveness of denosumab treatment despite of no substantial change in the tumor size.
KW - Denosumab
KW - Giant cell tumor of bone
KW - Magnetic resonance imaging
UR - http://www.scopus.com/inward/record.url?scp=85053123641&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053123641&partnerID=8YFLogxK
U2 - 10.2463/mrms.mp.2017-0072
DO - 10.2463/mrms.mp.2017-0072
M3 - Article
C2 - 29386457
AN - SCOPUS:85053123641
SN - 1347-3182
VL - 17
SP - 325
EP - 330
JO - Magnetic Resonance in Medical Sciences
JF - Magnetic Resonance in Medical Sciences
IS - 4
ER -